Accordingly, CXCL12 may be involved in the progression from PsO vulgaris to PsA, with MTX therapy reducing CXCL12 expression and disease severity, suggesting CXCL12 as a potential biomarker for psoriasis severity (Abdelaal et al., 2020). Here, CXCL12 is linked to psoriasis.